Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.
You may also be interested in...
Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin
Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.
Warner Chilcott’s Launch Of Atelvia Hits Headwinds
It has been a difficult year for Warner Chilcott PLC. But not an unexpected one.